US drug pricing reform happens at last
As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.
World Lung – Toxicity scuppers Amgen’s first-line lung hopes
In the Kras plus checkpoint inhibitor race it looks like advantage Mirati, for now.
Amgen picks its moment to strike for Chemocentryx
The $3.7bn price is cheaper than it would have been last year, but Tavneos must still fulfill its pipeline-in-a-product potential.
No plain sailing for Novartis’s PD-1 plan
Getting the Swiss firm’s Beigene-derived anti-PD-1 MAb across the US finish line is proving harder than expected.
The Cytomx paradox
Failure of the company’s in-house lead raises questions about the viability of its extensively partnered probody technology.
Teneo’s heavy chain success keeps on delivering
Yesterday’s takeout of Teneotwo came amid notable big pharma interest in the geeky science behind heavy chain-only antibodies.
Big pharma’s key third-quarter data
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
Asco 2022 – the spirit of Rova-T struggles to live on
DLL3, a pariah antigen after the implosion of Abbvie’s Rova-T, holds the interest of a handful of industry players.
